Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Third Harmonic Bio Inc. (THRD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: THRD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $3
1 Year Target Price $3
| 1 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 26.55% | Avg. Invested days 39 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 245.04M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 4 | Beta 2.15 | 52 Weeks Range 3.18 - 16.02 | Updated Date 06/29/2025 |
52 Weeks Range 3.18 - 16.02 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.24 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -14.6% | Return on Equity (TTM) -19.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -23565063 | Price to Sales(TTM) - |
Enterprise Value -23565063 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.09 | Shares Outstanding 45127800 | Shares Floating 15603387 |
Shares Outstanding 45127800 | Shares Floating 15603387 | ||
Percent Insiders 9.11 | Percent Institutions 80.72 |
Analyst Ratings
Rating 2 | Target Price 3 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Third Harmonic Bio Inc.
Company Overview
History and Background
Third Harmonic Bio, Inc. was founded in 2019 and is a clinical-stage biopharmaceutical company focused on developing a highly selective oral small-molecule inhibitor of KIT for the treatment of severe allergic diseases. It went public in September 2022. In December 2023, the company announced it will be acquired by Tourmaline Bio.
Core Business Areas
- Pharmaceutical Development: Focuses on developing oral small-molecule therapeutics for allergic diseases, specifically targeting the KIT receptor.
Leadership and Structure
The leadership team includes key executives in research and development, clinical operations, and business development. The organizational structure is typical of a clinical-stage biotech company, with a focus on drug development.
Top Products and Market Share
Key Offerings
- THB001: THB001 is Third Harmonic Bio's lead product candidate, an oral KIT inhibitor being developed for chronic urticaria (CSU) and other allergic diseases. Market share data is not yet available as it is still in clinical trials. Competitors include Xolair (omalizumab) by Novartis and Genentech and other emerging therapies from companies like Allakos and Sanofi.
Market Dynamics
Industry Overview
The pharmaceutical industry focusing on allergic diseases is characterized by a growing prevalence of conditions like chronic urticaria and asthma, driving demand for novel therapies. It's a competitive landscape with established players and emerging biotech companies.
Positioning
Third Harmonic Bio aims to differentiate itself with its oral, highly selective KIT inhibitor, targeting a key driver of mast cell activation in allergic diseases. Their competitive advantage lies in the potential for improved efficacy and convenience compared to existing therapies.
Total Addressable Market (TAM)
The global chronic spontaneous urticaria (CSU) market is estimated to reach billions of dollars. Third Harmonic Bio's THB001, if approved, could capture a significant share of this market by offering a novel treatment option. Market size is est. $3B.
Upturn SWOT Analysis
Strengths
- Novel oral KIT inhibitor with potential for improved efficacy
- Strong scientific team with experience in drug development
- Focus on a specific unmet medical need in allergic diseases
Weaknesses
- Single product pipeline, creating vulnerability
- Reliance on successful clinical trial outcomes
- Limited commercialization experience as a small biotech company
Opportunities
- Potential to expand THB001 into other allergic indications
- Partnerships with larger pharmaceutical companies for commercialization
- Positive clinical trial results leading to regulatory approval and market access
Threats
- Clinical trial failures
- Competition from established therapies and emerging competitors
- Regulatory hurdles and delays
- Changes to deal with Tourmaline Bio
Competitors and Market Share
Key Competitors
- SNY (Sanofi)
- NVS (Novartis)
- XOMA
Competitive Landscape
Third Harmonic Bio faces competition from established pharmaceutical companies with approved therapies for allergic diseases. Its advantage lies in a novel mechanism of action and oral administration, but it carries risks associated with clinical development.
Growth Trajectory and Initiatives
Historical Growth: The company's growth has been focused on advancing THB001 through clinical trials.
Future Projections: Future growth depends on the successful completion of clinical trials and potential commercialization of THB001. Analyst estimates will depend on the clinical trial results.
Recent Initiatives: Recent initiatives include advancing THB001 through Phase 1b trials and preparing for Phase 2 studies and agreeing to be acquired by Tourmaline Bio.
Summary
Third Harmonic Bio is a clinical-stage biopharmaceutical company developing a novel oral KIT inhibitor for allergic diseases. The company faces clinical trial risks, but the technology has the potential to gain market share by providing a more effective and convenient treatment option. The recent news that Tourmaline Bio will aquire the company means the stock price now reflects the price of the deal and the clinical trial risk has been eliminated for the shareholders. The recent private placement strengthens the balance sheet while advancing THB001 through trials.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is based on available information and estimates. Clinical trial results are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Third Harmonic Bio Inc.
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2022-09-14 | CEO & Director Ms. Natalie C. Holles | ||
Sector Healthcare | Industry Biotechnology | Full time employees 31 | Website https://www.thirdharmonicbio.com |
Full time employees 31 | Website https://www.thirdharmonicbio.com | ||
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It also develops THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated inflammatory diseases, respiratory, and gastrointestinal conditions. It has a license agreement with Novartis Pharma AG. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.